Last updated on July 2019

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)


Brief description of study

The purpose of this study is to compare the overall survival (OS) of participants with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin (EV) to the OS of participants treated with chemotherapy.

This study will also compare progression-free survival on study therapy (PFS1); the overall response rate (ORR) and the disease control rate (DCR) per Response Evaluation Criteria in Solid Tumors (RECIST) V1.1 of participants treated with EV to participants treated with chemotherapy.

In addition, this study will evaluate the duration of response (DOR) per RECIST V1.1 of EV and chemotherapy and assess the safety and tolerability of EV, as well as, the quality of life (QOL) and Patient Reported Outcomes (PRO) parameters.

Detailed Study Description

Participants considered an adult according to local regulation at the time of obtaining informed consent may participate in the study.

Clinical Study Identifier: NCT03474107

Find a site near you

Start Over

University of California

Sacramento, CA United States
  Connect »

Innovative Clinical Research

Whittier, CA United States
  Connect »

University of Colorado

Denver, CO United States
  Connect »

Florida Hospital

Orlando, FL United States
  Connect »

Piedmont Cancer Institute

Atlanta, GA United States
  Connect »

Norton Cancer Institute

Louisville, KY United States
  Connect »

Ochsner Clinic Foundation

New Orleans, LA United States
  Connect »

UMass Memorial Medical Center

Worcester, MA United States
  Connect »

Allina Health System

Minneapolis, MN United States
  Connect »

Queens Medical Associates

Fresh Meadows, NY United States
  Connect »

Long Island Jewish Medical Center

Lake Success, NY United States
  Connect »

W.G. Hefner VA Medical Center

Salisbury, NC United States
  Connect »

Dayton Physicians LLC

Dayton, OH United States
  Connect »

University of Pennsylvania

Philadelphia, PA United States
  Connect »

Fox Chase Cancer Center

Philadelphia, PA United States
  Connect »

Lifespan Rhode Island Hospital

Providence, RI United States
  Connect »

Saint Francis Hospital

Greenville, SC United States
  Connect »

Medical College of Wisconsin

Milwaukee, WI United States
  Connect »

Site AU61006

Adelaide, Australia
  Connect »

Site AU61003

Douglas, Australia
  Connect »

Site AU61001

Miranda, Australia
  Connect »

Site AU61004

St. Leonards, Australia
  Connect »

Site AU61002

Sydney, Australia
  Connect »

Site BE32010

Charleroi, Belgium
  Connect »

Site BE32005

Hasselt, Belgium
  Connect »

Site BE32003

Leuven, Belgium
  Connect »

Site BE32009

Liège, Belgium
  Connect »

Site BE32002

Roeselare, Belgium
  Connect »

Site CA15015

Calgary, Canada
  Connect »

Site CA15012

Edmonton, Canada
  Connect »

Site CA15003

Hamilton, Canada
  Connect »

Site CA15007

Montreal, Canada
  Connect »

Site CA15002

Quebec, QC Canada
  Connect »

Site CA15004

Quebec, QC Canada
  Connect »

Site CA15008

Saskatoon, Canada
  Connect »

Site CA15001

Sherbrooke, Canada
  Connect »

Site CA15005

Toronto, Canada
  Connect »

Site CA15013

Vancouver, Canada
  Connect »

Site DK45003

Aalborg, Denmark
  Connect »

Site DK45004

Copenhagen, Denmark
  Connect »

Site DN45001

Herlev, Denmark
  Connect »

Site FR33021

Besancon, France
  Connect »

Site FR33009

Bordeaux, France
  Connect »

Site FR33018

Bordeaux, France
  Connect »

Site FR33014

Marseille, France
  Connect »

Site FR33020

Montpellier, France
  Connect »

Site FR33005

Pierre-Bénite, France
  Connect »

Site FR33004

Saint-Mande, France
  Connect »

Site FR33002

Strasbourg, France
  Connect »

Site FR33019

Toulouse, France
  Connect »

Site IT39014

Reggio Emilia, Italy
  Connect »

Site IT39006

San Giovanni Rotondo, Italy
  Connect »

Site JP81010

Hirosaki, Japan
  Connect »

Site JP81009

Kita-gun, Japan
  Connect »

Site JP81002

Yokohama, Japan
  Connect »

Site JP81016

Osakasayama, Japan
  Connect »

Site JP81008

Bunkyo-ku, Japan
  Connect »

Site JP81013

Shinjuku-ku, Japan
  Connect »

Site JP81004

Hiroshima, Japan
  Connect »

Site KR82006

Daejeon, Korea, Republic of
  Connect »

Site KR82007

Goyang-Si, Korea, Republic of
  Connect »

Site KR82002

Incheon, Korea, Republic of
  Connect »

Site KR82001

Seongnam-si, Korea, Republic of
  Connect »

Site KR82003

Seoul, Korea, Republic of
  Connect »

Site KR82004

Seoul, Korea, Republic of
  Connect »

Site KR82008

Seoul, Korea, Republic of
  Connect »

Site KR82009

Seoul, Korea, Republic of
  Connect »

Site KR82005

Shin, Korea, Republic of
  Connect »

Site NL31002

Amsterdam, Netherlands
  Connect »

Site NL31003

Amsterdam, Netherlands
  Connect »

Site PT35102

Lisbon, Portugal
  Connect »

Site PT35106

Porto, Portugal
  Connect »

Site ES34014

Córdoba, Spain
  Connect »

Site ES34007

Valencia, Spain
  Connect »

Site TW88602

Kaohsiung, Taiwan
  Connect »

Site TW88605

Kaohsiung, Taiwan
  Connect »

Site TW88606

Taichung, Taiwan
  Connect »

Site TW88607

Taoyuan, Taiwan
  Connect »

Site GB44005

London, United Kingdom
  Connect »

Site GB44011

Southampton, United Kingdom
  Connect »

Site BE32009

Liège, Belgium
  Connect »

Site FR33005

Pierre-Bénite, France
  Connect »

Site ES34014

Córdoba, Spain
  Connect »

Site AR54001

Buenos Aires, Argentina
  Connect »

Site BE32009

Liège, Belgium
  Connect »

Site FR33005

Pierre-Bénite, France
  Connect »

Site JP81024

Takatsuki, Japan
  Connect »

Site ES34014

Córdoba, Spain
  Connect »

Site BE32009

Liège, Belgium
  Connect »

Site FR33005

Pierre-Bénite, France
  Connect »

Site ES34014

Córdoba, Spain
  Connect »

Site BE32009

Liège, Belgium
  Connect »

Site FR33005

Pierre-Bénite, France
  Connect »

Site NL31001

Tilburg, Netherlands
  Connect »

Site ES34001

Barcelona, Spain
  Connect »

Site ES34014

Córdoba, Spain
  Connect »

Site BE32009

Liège, Belgium
  Connect »

Site FR33005

Pierre-Bénite, France
  Connect »

Site ES34014

Córdoba, Spain
  Connect »

Site BE32009

Liège, Belgium
  Connect »

Site FR33005

Pierre-Bénite, France
  Connect »

Site NL31009

Nijmegen, Netherlands
  Connect »

Site PT35105

Lisboa, Portugal
  Connect »

Site ES34002

Badalona, Spain
  Connect »

Site ES34014

Córdoba, Spain
  Connect »

Site ES34008

Valencia, Spain
  Connect »

Site BE32009

Liège, Belgium
  Connect »

Site FR33005

Pierre-Bénite, France
  Connect »

Site ES34014

Córdoba, Spain
  Connect »

Site BE32009

Liège, Belgium
  Connect »

Site FR33005

Pierre-Bénite, France
  Connect »

Site JP81021

Tokushima, Japan
  Connect »

Site ES34012

Barcelona, Spain
  Connect »

Site ES34014

Córdoba, Spain
  Connect »

Site GB44006

London, United Kingdom
  Connect »

Site BE32009

Liège, Belgium
  Connect »

Site FR33005

Pierre-Bénite, France
  Connect »

Site ES34014

Córdoba, Spain
  Connect »

Site AR54002

San Miguel de Tucumán, Argentina
  Connect »

Site BE32007

Brussels, Belgium
  Connect »

Site BE32009

Liège, Belgium
  Connect »

Site FR33005

Pierre-Bénite, France
  Connect »

Site RU70002

Ivanovo, Russian Federation
  Connect »

Site ES34014

Córdoba, Spain
  Connect »

Site AR54002

San Miguel de Tucumán, Argentina
  Connect »

Site BE32009

Liège, Belgium
  Connect »

Site FR33005

Pierre-Bénite, France
  Connect »

Site ES34014

Córdoba, Spain
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.